LINC02367: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC02367

NCBI ID: G101930452

LINC02367

Other Name(s): Long intergenic non-protein coding RNA 2367 | long intergenic non-protein coding RNA 2367

LINC02367: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

LINC02367 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified using RNA sequencing (RNA-seq) data. It is located between the intron 14 of HLA-DPZ gene and the exon 5 of the CD28 gene on chromosome 6p21. LINC02367 is 21.4 kilobases (kb) long and has a unique open reading frame (ORF) of 511 nucleotides. It is a non-coding RNA, which means that it does not have a protein coding sequence, but it can be expressed and translated into proteins using gene expression regulation.

Disease association

LINC02367 has been associated with several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. For example, LINC02367 has been associated with various types of cancer, including breast, ovarian, and colorectal cancer. It has also been associated with neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

Drug targeting

LINC02367 is a potential drug target for several reasons. Firstly, LINC02367 is expressed in various tissues and cells, which makes it a potential drug target that can be targeted without ethical concerns. Secondly, LINC02367 has been shown to play a role in several cellular processes, including cell adhesion, migration, and survival. This suggests that it may be a good target for drugs that are designed to modulate these processes. Finally, LINC02367 has been shown to interact with several proteins, including the protein kinase B-DMBL. This suggests that it may be a good target for drugs that are inhibitors of B-DMBL signaling.

Biomarker

LINC02367 may also be used as a biomarker for several reasons. Firstly, it is a non-coding RNA, which makes it difficult to detect using traditional RNA-based assays. However, RNA-based assays can be used to detect LINC02367 expression, which can be used as a proxy for its levels in the cell. Secondly, LINC02367 has been shown to play a role in several cellular processes, including cell adhesion, migration, and survival. This suggests that it may be a good biomarker for evaluating the efficacy of drugs that are designed to modulate these processes. Finally, since LINC02367 is a non-coding RNA, it is not subject to the same genetic variations that are associated with coding RNAs. This makes it a more reliable biomarker than some coding RNAs.

Conclusion

LINC02367 is a long intergenic non-protein-coding RNA that has been associated with several diseases. It is a potential drug target due to its expression in various tissues and cells and its role in several cellular processes. Additionally, LINC02367 may be used as a biomarker for evaluating the efficacy of drugs that are designed to modulate these processes. Further studies are needed to confirm its potential as a drug target and to determine its utility as a biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2367

The "LINC02367 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02367 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets